Reversal of Battle-Related Aging (ROBRA) in a Special Operations Forces Cohort

This observational cohort study (n=20) aims to investigate the impact of a combined protocol of subanesthetic ketamine infusions (SKI) and bilateral cervical sympathetic blocks (CSB) on ageing in Special Operations Forces (SOF) members undergoing treatment for PTSD/TBI.

Sponsored by the Stella Center and led by Eugene Lipov, MD, the study aims to enrol 20 participants recruited from SOF with an active duty history of at least 5 years, aged between 40 and 60 years old. Participants must have a confirmed diagnosis of PTSD and will undergo treatment with SKI and CSB.

The primary outcome measure is the change from baseline in epigenetic ageing measured by the GrimAge epigenetic clock tool at 15, 90, and 180 days. Secondary objectives include assessing the impact on PTSD symptoms, mental health, free testosterone levels, and C-reactive protein levels over the same time frame.

The study started on July 5, 2023, with an estimated completion date of April 5, 2024. Recruitment is ongoing at Stella Center in Westmont, Illinois, United States.

Topic PTSD Traumatic Brain Injury
Compound Ketamine
Country United States of America
Visit trial
Status Recruiting
Results Published No
Start date 05 July 2023
End date 05 April 2024
Phase Not Applicable
Design Open
Type Observational
Generation First
Participants 20
Sex All
Age 40- 60
Therapy No

Trial Details

The purpose of this study is to examine measures of GrimAge clock in SOF members undergoing treatment for PTSD/TBI using CSB.

Trial Number NCT05855876

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.